MA26807A1 - METHODE POUR INHIBER L'AGREGATION DES PROTEINES AMYLOiDES ET POUR L'IMAGERIE DES DEPOTS DE PROTEINES AMYLOiDES AU MOYEN DE DERIVES D'ISOINDOLINE - Google Patents

METHODE POUR INHIBER L'AGREGATION DES PROTEINES AMYLOiDES ET POUR L'IMAGERIE DES DEPOTS DE PROTEINES AMYLOiDES AU MOYEN DE DERIVES D'ISOINDOLINE

Info

Publication number
MA26807A1
MA26807A1 MA26467A MA26467A MA26807A1 MA 26807 A1 MA26807 A1 MA 26807A1 MA 26467 A MA26467 A MA 26467A MA 26467 A MA26467 A MA 26467A MA 26807 A1 MA26807 A1 MA 26807A1
Authority
MA
Morocco
Prior art keywords
amyloid protein
imaging
inhibiting
isoindoline derivatives
deposits
Prior art date
Application number
MA26467A
Other languages
English (en)
Inventor
Yingjie Lai
Annette Theresa Sakkab
Lary Craswell Walker
Corinne Elizab Augelli-Szafran
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA26807A1 publication Critical patent/MA26807A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA26467A 1999-06-10 2002-01-03 METHODE POUR INHIBER L'AGREGATION DES PROTEINES AMYLOiDES ET POUR L'IMAGERIE DES DEPOTS DE PROTEINES AMYLOiDES AU MOYEN DE DERIVES D'ISOINDOLINE MA26807A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13854399P 1999-06-10 1999-06-10

Publications (1)

Publication Number Publication Date
MA26807A1 true MA26807A1 (fr) 2004-12-20

Family

ID=22482508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26467A MA26807A1 (fr) 1999-06-10 2002-01-03 METHODE POUR INHIBER L'AGREGATION DES PROTEINES AMYLOiDES ET POUR L'IMAGERIE DES DEPOTS DE PROTEINES AMYLOiDES AU MOYEN DE DERIVES D'ISOINDOLINE

Country Status (38)

Country Link
EP (1) EP1192131B1 (fr)
JP (1) JP2003502313A (fr)
KR (1) KR20020012266A (fr)
CN (1) CN1156445C (fr)
AP (1) AP1398A (fr)
AT (1) ATE272623T1 (fr)
AU (1) AU777747B2 (fr)
BG (1) BG106291A (fr)
BR (1) BR0011446A (fr)
CA (1) CA2373394A1 (fr)
CR (1) CR6530A (fr)
CZ (1) CZ20014366A3 (fr)
DE (1) DE60012742T2 (fr)
DK (1) DK1192131T3 (fr)
DZ (1) DZ3262A1 (fr)
EA (1) EA004405B1 (fr)
EE (1) EE200100666A (fr)
ES (1) ES2223531T3 (fr)
GE (1) GEP20043407B (fr)
HK (1) HK1046283B (fr)
HR (1) HRP20020027A2 (fr)
HU (1) HUP0201586A2 (fr)
IL (1) IL146455A0 (fr)
IS (1) IS6162A (fr)
MA (1) MA26807A1 (fr)
MX (1) MXPA01011112A (fr)
NO (1) NO20015992L (fr)
NZ (1) NZ515619A (fr)
OA (1) OA11958A (fr)
PL (1) PL352294A1 (fr)
PT (1) PT1192131E (fr)
SI (1) SI1192131T1 (fr)
SK (1) SK17622001A3 (fr)
TR (1) TR200200257T2 (fr)
UA (1) UA64842C2 (fr)
WO (1) WO2000076969A1 (fr)
YU (1) YU86801A (fr)
ZA (1) ZA200109164B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
AP2002002387A0 (en) * 1999-06-10 2002-03-31 Warner Lambert Co Method of inhibiting amyloid aggregation and imaging amyloid deposits.
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (fr) * 2000-09-29 2002-03-29 Warner-Lambert Company Analogues de phenoxazine pouvant etre utilises comme inhibiteurs d'agregation de substances amyloides et traitement de la maladie d'alzheimer et des troubles relatifs a l'amyloidose
GB0031302D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
GB2404855A (en) * 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
BRPI0719379A2 (pt) * 2006-11-24 2014-02-11 Ac Immune Sa Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
EP2121633A2 (fr) 2007-02-12 2009-11-25 Merck & Co., Inc. Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
WO2010000372A2 (fr) * 2008-06-09 2010-01-07 Ludwig-Maximilians-Universität München Nouveau médicament pour l’inhibition de l’agrégation des protéines impliquées dans des maladies associées à l’agrégation des protéines et/ou des maladies neurodégénératives
CN102325765B (zh) 2009-02-06 2014-12-24 杨森制药公司 作为γ-分泌酶调节剂的取代的双环杂环化合物
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
CA2755467A1 (fr) * 2009-05-07 2010-12-23 Janssen Pharmaceuticals, Inc. Nouveaux derives substitues d'indazole et d'aza-indazole utilises comme modulateurs de la gamma secretase
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
AU2011206635B2 (en) 2010-01-15 2015-01-22 Cellzome Limited Novel substituted triazole derivatives as gamma secretase modulators
AU2012230348A1 (en) 2011-03-24 2013-08-29 Cellzome Limited Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
MX368504B (es) * 2014-04-14 2019-10-04 Shanghai hengrui pharmaceutical co ltd Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
US11071793B2 (en) * 2014-08-29 2021-07-27 Chdi Foundation, Inc. Probes for imaging huntingtin protein
RS60906B1 (sr) 2014-10-06 2020-11-30 Vertex Pharma Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
PT3551622T (pt) 2016-12-09 2020-11-12 Vertex Pharma Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
WO2018140186A1 (fr) * 2017-01-28 2018-08-02 Kingchem Life Science Llc Procédé de préparation de 5-phénoxy-1(3h) isobenzofuranone
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018395A1 (fr) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CA3085006A1 (fr) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Procedes pour preparer des modulateurs du regulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MX2024000313A (es) 2021-07-09 2024-03-06 Plexium Inc Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide

Also Published As

Publication number Publication date
EP1192131A1 (fr) 2002-04-03
WO2000076969A1 (fr) 2000-12-21
ES2223531T3 (es) 2005-03-01
CN1355790A (zh) 2002-06-26
YU86801A (sh) 2004-07-15
PL352294A1 (en) 2003-08-11
CR6530A (es) 2004-03-24
ZA200109164B (en) 2003-02-06
PT1192131E (pt) 2004-11-30
EA004405B1 (ru) 2004-04-29
CA2373394A1 (fr) 2000-12-21
NO20015992D0 (no) 2001-12-07
JP2003502313A (ja) 2003-01-21
NZ515619A (en) 2003-05-30
CN1156445C (zh) 2004-07-07
DE60012742T2 (de) 2005-01-13
IS6162A (is) 2001-11-15
CZ20014366A3 (cs) 2002-11-13
DK1192131T3 (da) 2004-12-13
AU777747B2 (en) 2004-10-28
HK1046283B (zh) 2005-01-07
MXPA01011112A (es) 2002-06-04
BR0011446A (pt) 2002-03-19
OA11958A (en) 2006-04-13
AU5312000A (en) 2001-01-02
SI1192131T1 (en) 2004-12-31
DZ3262A1 (fr) 2000-12-12
HUP0201586A2 (en) 2002-08-28
NO20015992L (no) 2002-02-06
HRP20020027A2 (en) 2005-02-28
AP1398A (en) 2005-04-21
UA64842C2 (uk) 2004-03-15
EE200100666A (et) 2003-02-17
EP1192131B1 (fr) 2004-08-04
ATE272623T1 (de) 2004-08-15
IL146455A0 (en) 2002-07-25
AP2002002389A0 (en) 2002-03-31
SK17622001A3 (sk) 2003-06-03
GEP20043407B (en) 2004-05-10
EA200101133A1 (ru) 2002-06-27
TR200200257T2 (tr) 2002-06-21
DE60012742D1 (de) 2004-09-09
BG106291A (bg) 2002-05-31
HK1046283A1 (en) 2003-01-03
KR20020012266A (ko) 2002-02-15

Similar Documents

Publication Publication Date Title
DZ3262A1 (fr) Procede d'inhibition d'agregation de proteines amyloides et d'imagerie de depots amyloides au moyen de derives d'isoindoline
MA26805A1 (fr) METHODE POUR INHIBER L'AGREGATION DE PROTEINES AMYLOiDES, ET POUR L'IMAGERIE DES DEPOTS DE PROTEINES AMYLOiDES.
WO2002013744A3 (fr) Procede d'application d'elastiques courbes pour ouvertures pour les jambes au moyen d'elements d'appui presentant des surfaces courbes
EP1027455A4 (fr) Procedes et compositions pour cibler les processus metaboliques des adn au moyen de derives d'aminoglucosides
MA26449A1 (fr) Derives d'acides amines .
FR2799554B1 (fr) Composition d'elimination de photoresist et procede pour eliminer un photoresist au moyen de cette composition
FR2805259B1 (fr) Nouveaux derives d'aminoacides n-mercaptoacyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NO20014528L (no) Fremgangsmåte for påvisning av megsinprotein og anvendelse av dette
EP1631262A4 (fr) Systeme et procede ameliores pour faciliter l'hemostase au moyen d'une eponge absorbable
ITPI990073A0 (it) Contenitore igienizzante per spazzolini da denti e spazzole in genere
FR2755432B1 (fr) Conditionnement pour des animaux aquatiques vivants, notamment des huitres
EP1434604A4 (fr) 4-halo-ethenylphenyltropane: agents d'imagerie pour les transporteurs de serotonine
EP0989860A4 (fr) Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees
AU5311800A (en) Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits
FR2797582B1 (fr) Sachet de conditionnement de substances liquides pour l'insemination artificielle animale
EP1581250A4 (fr) Formulations orales permettant d'administrer des proteines et des polypeptides
WO2002011772A3 (fr) Proteines de transport de metal radiomarquees utilisees en tant qu'agents d'imagerie
FR2794613B1 (fr) Borne de proprete pour animaux
DE60014616D1 (de) Antikörper gegen plazentaprotein 13
FR2776670B1 (fr) Procede de detection de lesions de l'adn au moyen de complexes de proteines et elements permettant la mise en oeuvre du procede
DE69940319D1 (de) Amsh protein und dessen cdns
FR2794621B1 (fr) Procede de deformation permanente des cheveux au moyen d'un materiau filiforme
ITBO20000735A0 (it) Macchine e metodo per l'incarto di prodotti
FR2769174B1 (fr) Matelas pour animaux
FR2807642B1 (fr) Ameliorations introduites dans les catheters pour l'insemination artificielle des lapines